What internal levers can drive the expected Q4 improvement, and why is the NOL rights plan being implemented now?

Ed highlighted internal levers for Q4 improvement, including additional cost reductions beyond the initial $125 million, improved sales execution, and faster implementation of logistics provider arrangements. Jon explained the NOL plan was prompted by a review during the balance sheet optimization and recent large shareholder activity, aiming to protect over $200 million in NOL carryforwards from inadvertent ownership changes. “We saw that we were halfway to potentially having a problem should the shareholders continue to buy.”

What specifically drove the need to pause cost reduction efforts, and can you provide more detail on the noncore assets being sold?

Ed clarified that the pause in cost reductions was due to the massive amount of costs already removed (over $125 million annualized) following the commercial payer transition and PNHS divestiture, requiring time to stabilize the business. He explained that the noncore asset sales were for very small, legacy businesses not aligned with the current pure-play model, with one already closed and another expected soon. “We took out more than $125 million of annualized cost as we rolled into this year... we did take a pause because we wanted to stabilize the business.”

How will free cash flow improve in H2, especially with a low cash balance, and how will the revolver and ATM be utilized for liquidity?

Jon stated that FCF improvement in H2 would be primarily EBITDA-driven, with Q4 stronger than Q3. He clarified that the ATM is a small program with dilution spread over time. He explained that cash levels would remain low as funds are used for debt repayment or investment, and the revolver would be drawn only occasionally for working capital lumpiness, not continuously, unlike in the past. “The revolver will be drawn occasionally as based on lumpiness in working capital very much unlike what we saw in the past was continuously drawn.”

ACH

Accendra Health (ACH) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 10, 2026

Source: earnings call transcript

Executive summary

Accendra Health Q2 FY26 — CEO Retirement, Revised Outlook, and Payer Collection Headwinds

Accendra Health reported a challenging Q2 FY26, missing expectations due to slower revenue growth and significant headwinds from payer collection issues, which negatively impacted both revenue and EBITDA. The company has revised its full-year guidance downwards but is implementing cost reduction initiatives and securing new commercial agreements, expecting a stronger Q4 to set the stage for 2027. The CEO also announced his retirement by year-end, initiating a succession process.

Highlights

Q2 revenue, excluding the impact of a large commercial payer exit, grew 2% YoY, with mid-single-digit growth in the sleep category (5.5%) and 4% in diabetes.
Successfully completed balance sheet optimization in June, reducing total debt by nearly $400 million and net debt by over $55 million since March.
Secured key commercial agreements, including the renewal of the largest soft good contract with a major payer and a new sole-source agreement with a regional health system launching in early 2027.
Identified and eliminated over $125 million of annualized costs earlier in the year, with additional cost reductions executed in Q3.

Concerns

Q2 financial results did not meet expectations, with revenue growth below forecasts and adjusted EBITDA at just over $60 million.
Slower-than-expected recovery of collection rates negatively impacted revenue and adjusted EBITDA by approximately $10 million in Q2 and $20 million for the first half of the year.
Full-year 2026 revenue guidance revised down to $2.45 billion - $2.55 billion (from previous higher expectations).
Full-year 2026 adjusted EBITDA guidance revised down to $300 million - $320 million (from previous higher expectations).
Fully levered free cash flow for FY26 revised to breakeven to slightly positive, down from prior expectations.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$2.45 billion - $2.55 billion high materiality	FY26	Medium
Full-year 2026 Adjusted EBITDA	$300 million - $320 million high materiality	FY26	Medium
Full-year 2026 Free Cash Flow (fully levered)	breakeven to slightly positive high materiality	FY26	Medium
Annual Free Cash Flow (normalized)	around $100 million medium materiality	Annual	High

Deals & partnerships

Largest commercial payer Renewal of largest soft good contract for years to come

Renewal of the largest soft good contract with the largest commercial payer was formally executed during the second quarter.

Regional health system New sole-source agreement

Signed a new sole-source agreement with a regional health system that is expected to launch in early 2027.

Another payer Broader enterprise-wide fee-for-service agreement

Executed a broader enterprise-wide fee-for-service agreement with another payer to drive additional patient volume and improve capacity utilization.

Not specified Sale of small noncore asset

Closed on the sale of a small noncore asset at the end of July.

Not specified Sale of another small noncore asset

Expect another small noncore asset sale to close in late Q3 or early Q4.

Risks & headwinds

Slower-than-expected recovery of collection rates due to increased payer audit activity and inefficiencies. Near-term (Q2, Q3 FY26)

Approximately $10 million negative impact on revenue and adjusted EBITDA in Q2, and $20 million for H1 FY26.

Mitigation:Implemented mitigation plans with payers, seeing encouraging progress, with efforts trending toward resolution in Q3.

Revenue growth below expectations. Q2 FY26, expected to continue through Q3 FY26.

Q2 revenue growth (excluding large commercial payer exit) at 2%, below expectations.

Mitigation:Targeted changes within commercial and operational organizations, new agreements, and sales force reinvigoration.

Expenses as a percentage of revenue running above historic rates. Q1 and Q2 FY26.

Not quantified, but stated as a 'drag on adjusted EBITDA'.

Mitigation:Actions planned and underway to address both cost of net revenue and SG&A.

Potential for inadvertent loss of Net Operating Loss (NOL) tax attributes due to shareholder trading activity. Ongoing.

NOL carryforwards exceed $200 million going into 2027.

Mitigation:Implementing a Net Operating Loss (NOL) rights plan to protect the value of these tax attributes.

What to watch in Q3 FY26

Payer collection rate recovery

Q3 FY26

Current ~$10M negative impact in Q2, ~$20M in H1 FY26

Target Resolution of audit issues, improved cash flow, reduced income statement impact

Why it matters

Critical for improving revenue, adjusted EBITDA, and free cash flow, as it has been a significant drag.

Efforts are constructively trending toward resolution in the third quarter, and we believe realized cash flow will improve upon conclusion.

Find out whether ACH delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you elaborate on the payer collection issues, confirm no supplier contract terminations, and clarify if the expected strong Q4 is indicative of a normalized run-rate for 2027?

Management explained that payer audits increased exponentially, causing payment delays and diverting resources, but progress is being made towards resolution in Q3. They confirmed no supplier contracts have been terminated and that Q4 is expected to be the best quarter, serving as a jump-off point for 2027 due to new agreements, sales execution, sleep center expansion, and cost reductions.

“Q4 will be the jump-off point really for 2027.”

asked by Kevin Caliendo · answered by Edward Pesicka

2 min read 5 chapters

Detailed narrative

CEO Transition and Strategic Foundation

Ed Pesicka announced his retirement by the end of 2026, marking the culmination of an 8-year tenure focused on stabilizing the company, navigating the pandemic, divesting the PNHS segment, and optimizing the balance sheet. The Board has a succession plan in place, aiming for a smooth transition to a new CEO who will build on the established pure-play home-based healthcare business.

This decision reflects a belief that the company is well-positioned for its next chapter after significant foundational milestones.

Q2 Performance and Headwinds

The company's Q2 results fell short of expectations, primarily due to revenue growth below forecast, delayed timing of planned cost reductions, and a slower-than-expected recovery in collection rates. These discrete headwinds, particularly from an exponential increase in payer audit activity and inefficiencies, negatively impacted revenue and adjusted EBITDA by approximately $10 million in Q2 and $20 million year-to-date.

Management expects these collection issues to resolve in Q3.

Cost Optimization and Operational Efficiency

Accendra Health previously eliminated over $125 million in annualized costs following its separation from Owens & Minor and the exit of a large commercial payer. After a period of stabilization, the company has initiated the next phase of targeted cost reductions in Q3 and is exploring new arrangements with logistics providers to lower operating costs and reduce inventory.

These efforts are expected to drive operational savings and working capital improvements, contributing to future profitability.

Commercial Momentum and Strategic Agreements

Despite the challenges, the company reported progress in strategic initiatives. This includes the formal execution of a renewed soft good contract with its largest commercial payer, a new sole-source agreement with a regional health system launching in early 2027, and an enterprise-wide fee-for-service agreement with another payer to drive patient volume and capacity utilization.

The national rollout of the sleep center of excellence is also advancing, expected to contribute to growth and profitability in late 2026 and 2027.

Balance Sheet and Liquidity Management

Accendra Health successfully completed a balance sheet optimization in June, reducing total debt by nearly $400 million and net debt by over $55 million since March, extending debt maturities to 2029. To further strengthen its financial profile, the company plans to activate a small at-the-market (ATM) equity program for debt reduction and implement a Net Operating Loss (NOL) rights plan to protect its valuable tax attributes, which exceed $200 million, from inadvertent ownership changes.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.